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Letter to theEditorThe Authors’ Reply
Sebastian Pratschke, MD1 and Martin K. Angele, MD1Thank you very much for your comment on our manu-script “Results of the TOP Study: Prospectively Ran-
domized Multicenter Trial of an Ex Vivo Tacrolimus Rinse
Before Transplantation in EDC Livers.”1 We would like to
take the opportunity to respond to the valuable comments
of Kobayashi.2
In the tacrolimus organ perfusion (TOP) study marginal
liver grafts exhibiting ≥ 2 extended donor criteria (EDC)
were randomly flushed ex situ with Tacrolimus (20 ng/mL)
dissolved in histidine tryptophane ketoglutarate (HTK) solu-
tion or with HTK only (control) to reduce ischemia reperfu-
sion injury. Kobayashi suspects a potential warming of the
grafts and harmful effects through this procedure. Facing this
criticism, the authors state that the temperature of the rinse
solution was 4°C at the beginning of the treatment (though
it was not measured at the end of the perfusion as suggested
by Kobayashi) and the procedure took on an average of
18 minutes only. Although the plastic bags containing the
rinse solution were not cooled during the procedure (analo-
gously with the systemic perfusion at organ harvesting),
grafts undergoing the study treatment were continuously
stored on ice until the beginning of implantation. Therefore,
the authors assume a warming of the graft and a subsequent
initiation of the hepatic metabolism to be extremely unlikely.
Moreover, Kobayashi questions the anastomosis time and as-
sumes that warm ischemia could counteract the protective ef-
fects of a rinse treatment. In this respect, he suggests a new in
situ technique of organ perfusion. The authors would like to
state that changes in the surgical procedure were beyond the
scope of the TOP Study. Moreover, the rinse treatment itselfReceived 14 July 2016. Revision requested 9 December 2016.
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Transplantation DIRECT ■ 2017was not the point of interest in our study, but to investigate
the effects of Tacrolimus in a rinse of 1000 ml HTK com-
pared to 1000 ml HTK only. Cava sparing transplantation
including anastomoses was performed after the rinse treat-
ment according to center specific standards in both groups.
Therefore, the study treatment did not affect the time for vas-
cular reconstruction. To the authors' best knowledge, a sim-
ple study treatment in combination with routine surgery is
required to generate valid data in a multicentric trial in liver
transplantation.
Kobayashi presents an interesting concept of an in-situ
perfusion. The authors greatly appreciate any attempts (ie,
organ preperfusion) to improve the utilization of EDC grafts.
In this respect, an additional in situ flush of the graft may
have protective effects. Nonetheless, this procedure does
not represent an established procedure and would need to
be evaluated in a prospective trial. Since the TOP study failed
to show protective effects of Tacrolimus compared with con-
trol, this concept must be reevaluated and the authors suggest
further analyses of this substance due to its proven anti-
inflammatory effects. Therefore, an adjunct of Tacrolimus to
an in-situ perfusion as described by Kobayashi or to machine
perfusion could be an option to reduce ischemia reperfusion
injury especially in EDC grafts thereby increasing the limited
donor pool, which represents the most pressing problem in to-
day’s transplantation medicine.
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